Carolina Schinke
Concepts (322)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 80 | 2025 | 3049 | 9.320 |
Why?
| Antibodies, Bispecific | 10 | 2025 | 94 | 3.810 |
Why?
| B-Cell Maturation Antigen | 9 | 2025 | 98 | 2.510 |
Why?
| Hematopoietic Stem Cell Transplantation | 8 | 2024 | 603 | 1.920 |
Why?
| Bone Marrow | 11 | 2024 | 364 | 1.340 |
Why?
| Neoplasm, Residual | 7 | 2025 | 173 | 1.330 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 5 | 2025 | 125 | 1.330 |
Why?
| Leukemia, Plasma Cell | 2 | 2020 | 33 | 1.300 |
Why?
| Humans | 95 | 2025 | 52483 | 1.280 |
Why?
| Neoplasms, Plasma Cell | 3 | 2024 | 37 | 1.260 |
Why?
| Paraproteinemias | 2 | 2022 | 74 | 1.250 |
Why?
| Positron-Emission Tomography | 5 | 2025 | 301 | 1.190 |
Why?
| Immunotherapy, Adoptive | 6 | 2024 | 166 | 1.140 |
Why?
| Diffusion Magnetic Resonance Imaging | 3 | 2025 | 133 | 1.080 |
Why?
| Neoplasm Recurrence, Local | 8 | 2025 | 649 | 1.070 |
Why?
| Aged | 29 | 2025 | 10121 | 1.010 |
Why?
| Immunoglobulin Light Chains | 2 | 2017 | 90 | 0.990 |
Why?
| Prognosis | 18 | 2025 | 2099 | 0.940 |
Why?
| Transplantation, Autologous | 9 | 2024 | 488 | 0.930 |
Why?
| Immunoglobulins, Intravenous | 1 | 2025 | 63 | 0.910 |
Why?
| Gene Expression Regulation, Neoplastic | 10 | 2024 | 857 | 0.900 |
Why?
| Myelodysplastic Syndromes | 5 | 2016 | 86 | 0.870 |
Why?
| Immunoconjugates | 2 | 2022 | 39 | 0.860 |
Why?
| Mutation | 8 | 2022 | 1347 | 0.850 |
Why?
| Middle Aged | 28 | 2025 | 13028 | 0.850 |
Why?
| Antibodies, Monoclonal | 6 | 2023 | 481 | 0.780 |
Why?
| Male | 36 | 2025 | 26761 | 0.760 |
Why?
| Leukemia, Myeloid, Acute | 4 | 2019 | 203 | 0.750 |
Why?
| Gene Expression Profiling | 11 | 2025 | 1105 | 0.750 |
Why?
| Health Personnel | 1 | 2024 | 256 | 0.730 |
Why?
| Adult | 24 | 2025 | 14161 | 0.730 |
Why?
| Testis | 1 | 2021 | 72 | 0.690 |
Why?
| Signal Transduction | 6 | 2024 | 1671 | 0.680 |
Why?
| Aged, 80 and over | 12 | 2025 | 3392 | 0.660 |
Why?
| Tumor Microenvironment | 5 | 2024 | 256 | 0.660 |
Why?
| Hematopoietic Stem Cells | 3 | 2019 | 187 | 0.650 |
Why?
| Plasma Cells | 6 | 2025 | 239 | 0.630 |
Why?
| Quality of Life | 1 | 2025 | 879 | 0.630 |
Why?
| Cell Proliferation | 8 | 2023 | 1023 | 0.620 |
Why?
| Clonal Evolution | 4 | 2024 | 58 | 0.620 |
Why?
| Female | 32 | 2025 | 28171 | 0.620 |
Why?
| Gene Expression | 3 | 2018 | 618 | 0.610 |
Why?
| Clinical Trials as Topic | 6 | 2023 | 467 | 0.550 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 1031 | 0.550 |
Why?
| Translocation, Genetic | 5 | 2021 | 265 | 0.540 |
Why?
| Thoracic Neoplasms | 1 | 2016 | 13 | 0.510 |
Why?
| Plasmacytoma | 1 | 2016 | 43 | 0.490 |
Why?
| Receptors, Interleukin-8B | 1 | 2015 | 5 | 0.480 |
Why?
| Survival Analysis | 8 | 2024 | 673 | 0.470 |
Why?
| Interleukin-8 | 1 | 2015 | 86 | 0.460 |
Why?
| Receptors, G-Protein-Coupled | 2 | 2024 | 56 | 0.430 |
Why?
| Antineoplastic Agents | 7 | 2024 | 1222 | 0.410 |
Why?
| Combined Modality Therapy | 4 | 2024 | 639 | 0.400 |
Why?
| Fluorodeoxyglucose F18 | 5 | 2021 | 188 | 0.390 |
Why?
| Neutropenia | 2 | 2023 | 115 | 0.380 |
Why?
| DNA Methylation | 4 | 2020 | 592 | 0.370 |
Why?
| Oncogene Proteins, Fusion | 2 | 2018 | 61 | 0.370 |
Why?
| Neoplasms, Second Primary | 2 | 2024 | 77 | 0.370 |
Why?
| Chromosomes, Human, Pair 1 | 3 | 2023 | 96 | 0.360 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 48 | 0.360 |
Why?
| Stem Cell Transplantation | 3 | 2022 | 185 | 0.350 |
Why?
| Evolution, Molecular | 2 | 2021 | 93 | 0.350 |
Why?
| Epigenesis, Genetic | 4 | 2020 | 406 | 0.340 |
Why?
| Tretinoin | 1 | 2010 | 54 | 0.330 |
Why?
| Treatment Outcome | 10 | 2025 | 5422 | 0.320 |
Why?
| Cell Line, Tumor | 7 | 2024 | 1470 | 0.320 |
Why?
| Risk Assessment | 4 | 2024 | 1327 | 0.310 |
Why?
| Transcription Factors | 3 | 2023 | 566 | 0.310 |
Why?
| Transcriptome | 3 | 2025 | 370 | 0.310 |
Why?
| Immunoglobulin kappa-Chains | 2 | 2021 | 22 | 0.310 |
Why?
| Disease Progression | 8 | 2025 | 871 | 0.300 |
Why?
| DNA-Binding Proteins | 2 | 2021 | 422 | 0.280 |
Why?
| Neoplasm Proteins | 3 | 2020 | 334 | 0.280 |
Why?
| Melanoma | 1 | 2010 | 288 | 0.270 |
Why?
| RANK Ligand | 2 | 2024 | 187 | 0.250 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 91 | 0.250 |
Why?
| Biopsy | 2 | 2018 | 605 | 0.240 |
Why?
| Radiopharmaceuticals | 3 | 2021 | 204 | 0.230 |
Why?
| Skin Neoplasms | 1 | 2010 | 505 | 0.230 |
Why?
| Chemokine CCL3 | 1 | 2024 | 13 | 0.230 |
Why?
| HMGB1 Protein | 1 | 2024 | 21 | 0.230 |
Why?
| Retrospective Studies | 7 | 2025 | 6607 | 0.230 |
Why?
| Dexamethasone | 3 | 2024 | 438 | 0.230 |
Why?
| T-Lymphocytes | 5 | 2024 | 340 | 0.220 |
Why?
| Kaplan-Meier Estimate | 3 | 2021 | 483 | 0.220 |
Why?
| Chemokine CXCL12 | 1 | 2024 | 32 | 0.220 |
Why?
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2024 | 2 | 0.220 |
Why?
| Antigens, CD19 | 1 | 2024 | 28 | 0.220 |
Why?
| Mutation Rate | 2 | 2021 | 36 | 0.210 |
Why?
| Bone Resorption | 2 | 2024 | 302 | 0.210 |
Why?
| Recurrence | 6 | 2025 | 672 | 0.210 |
Why?
| Genome-Wide Association Study | 1 | 2024 | 186 | 0.210 |
Why?
| Myeloproliferative Disorders | 1 | 2023 | 31 | 0.210 |
Why?
| Cell Cycle | 2 | 2021 | 230 | 0.210 |
Why?
| Neoplasm Staging | 2 | 2024 | 772 | 0.200 |
Why?
| Genomics | 2 | 2023 | 268 | 0.200 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2020 | 81 | 0.190 |
Why?
| Drug Resistance, Neoplasm | 1 | 2024 | 326 | 0.190 |
Why?
| Osteolysis | 1 | 2022 | 75 | 0.190 |
Why?
| Qualitative Research | 1 | 2024 | 364 | 0.190 |
Why?
| Drug Approval | 1 | 2022 | 46 | 0.190 |
Why?
| Waldenstrom Macroglobulinemia | 1 | 2022 | 40 | 0.190 |
Why?
| Lymphoma, B-Cell | 1 | 2022 | 61 | 0.190 |
Why?
| Osteocytes | 1 | 2024 | 226 | 0.190 |
Why?
| Bone Marrow Transplantation | 1 | 2022 | 113 | 0.190 |
Why?
| Hematologic Diseases | 1 | 2021 | 21 | 0.180 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2024 | 505 | 0.180 |
Why?
| Epigenomics | 1 | 2021 | 75 | 0.180 |
Why?
| Patient Participation | 1 | 2022 | 69 | 0.180 |
Why?
| Genetic Predisposition to Disease | 1 | 2024 | 528 | 0.180 |
Why?
| Abnormal Karyotype | 1 | 2021 | 6 | 0.180 |
Why?
| Chromosome Deletion | 2 | 2023 | 142 | 0.180 |
Why?
| Mice | 6 | 2024 | 5949 | 0.180 |
Why?
| Drug Design | 2 | 2013 | 120 | 0.180 |
Why?
| Myeloma Proteins | 1 | 2021 | 26 | 0.180 |
Why?
| Immunoglobulin A | 1 | 2021 | 45 | 0.180 |
Why?
| Risk Factors | 8 | 2024 | 3889 | 0.180 |
Why?
| Communicable Diseases | 1 | 2021 | 55 | 0.170 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 236 | 0.170 |
Why?
| Genes, Tumor Suppressor | 2 | 2021 | 74 | 0.170 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2020 | 32 | 0.170 |
Why?
| Hematologic Neoplasms | 1 | 2022 | 106 | 0.170 |
Why?
| Salvage Therapy | 1 | 2021 | 136 | 0.170 |
Why?
| Immunoglobulin G | 1 | 2021 | 195 | 0.170 |
Why?
| Practice Guidelines as Topic | 1 | 2023 | 488 | 0.170 |
Why?
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.170 |
Why?
| Neoplasm Invasiveness | 1 | 2021 | 278 | 0.160 |
Why?
| Bone Diseases | 1 | 2021 | 96 | 0.160 |
Why?
| Gene Amplification | 1 | 2019 | 58 | 0.160 |
Why?
| Chromosomal Instability | 1 | 2019 | 16 | 0.160 |
Why?
| Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.160 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 111 | 0.160 |
Why?
| Atrial Fibrillation | 1 | 2022 | 200 | 0.160 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 10 | 0.150 |
Why?
| United States | 3 | 2024 | 5192 | 0.150 |
Why?
| Comorbidity | 1 | 2021 | 625 | 0.150 |
Why?
| Models, Statistical | 1 | 2020 | 230 | 0.150 |
Why?
| Sulfonamides | 1 | 2019 | 133 | 0.150 |
Why?
| Healthcare Disparities | 1 | 2022 | 299 | 0.150 |
Why?
| Spleen | 1 | 2019 | 172 | 0.150 |
Why?
| Animals | 8 | 2024 | 13505 | 0.150 |
Why?
| Spinal Fractures | 1 | 2018 | 38 | 0.150 |
Why?
| Phosphotransferases | 1 | 2018 | 17 | 0.150 |
Why?
| Bacteremia | 1 | 2019 | 92 | 0.140 |
Why?
| Adipocytes | 1 | 2018 | 132 | 0.140 |
Why?
| Cell Differentiation | 3 | 2022 | 665 | 0.140 |
Why?
| Gene Rearrangement | 1 | 2018 | 75 | 0.140 |
Why?
| Disease-Free Survival | 4 | 2019 | 460 | 0.140 |
Why?
| Kidney Function Tests | 1 | 2017 | 54 | 0.140 |
Why?
| Hexokinase | 1 | 2017 | 16 | 0.140 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2017 | 35 | 0.140 |
Why?
| Calcification, Physiologic | 1 | 2017 | 42 | 0.130 |
Why?
| Glomerular Filtration Rate | 1 | 2017 | 124 | 0.130 |
Why?
| Survival Rate | 4 | 2020 | 945 | 0.130 |
Why?
| Chromosome Aberrations | 2 | 2023 | 297 | 0.130 |
Why?
| Pelvis | 1 | 2017 | 69 | 0.130 |
Why?
| Histoplasma | 1 | 2016 | 24 | 0.130 |
Why?
| CA-125 Antigen | 1 | 2016 | 16 | 0.130 |
Why?
| HIV Infections | 1 | 2021 | 389 | 0.130 |
Why?
| Receptor, TIE-2 | 1 | 2016 | 16 | 0.130 |
Why?
| Cardiomyopathy, Restrictive | 1 | 2016 | 5 | 0.130 |
Why?
| Histoplasmosis | 1 | 2016 | 47 | 0.130 |
Why?
| Urea | 1 | 2016 | 82 | 0.130 |
Why?
| Indazoles | 1 | 2016 | 47 | 0.130 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 94 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 179 | 0.120 |
Why?
| Remission Induction | 3 | 2024 | 218 | 0.120 |
Why?
| Gastrointestinal Diseases | 1 | 2016 | 125 | 0.120 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2017 | 221 | 0.120 |
Why?
| Proteasome Inhibitors | 1 | 2016 | 104 | 0.120 |
Why?
| Immunologic Factors | 1 | 2016 | 117 | 0.120 |
Why?
| Cell Cycle Checkpoints | 1 | 2015 | 32 | 0.120 |
Why?
| Kidney Diseases | 1 | 2017 | 220 | 0.120 |
Why?
| Time Factors | 2 | 2021 | 2968 | 0.120 |
Why?
| Cluster Analysis | 1 | 2015 | 233 | 0.110 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2015 | 220 | 0.110 |
Why?
| Myocardium | 1 | 2017 | 453 | 0.110 |
Why?
| Thrombopoiesis | 1 | 2014 | 5 | 0.110 |
Why?
| Hydrazines | 1 | 2014 | 17 | 0.110 |
Why?
| Benzoates | 1 | 2014 | 21 | 0.110 |
Why?
| Neoplastic Stem Cells | 1 | 2015 | 99 | 0.110 |
Why?
| Immunotherapy | 1 | 2016 | 244 | 0.110 |
Why?
| Cystatin M | 2 | 2024 | 19 | 0.110 |
Why?
| Disease Models, Animal | 2 | 2016 | 1478 | 0.100 |
Why?
| Cell Survival | 1 | 2015 | 612 | 0.100 |
Why?
| Pyrazoles | 1 | 2014 | 114 | 0.100 |
Why?
| Cross-Sectional Studies | 3 | 2023 | 1678 | 0.100 |
Why?
| Chromosomes, Human, Pair 7 | 1 | 2012 | 30 | 0.100 |
Why?
| Clone Cells | 2 | 2023 | 77 | 0.100 |
Why?
| STAT3 Transcription Factor | 1 | 2012 | 85 | 0.100 |
Why?
| Cardiovascular Diseases | 1 | 2017 | 490 | 0.100 |
Why?
| Chromatin | 2 | 2024 | 139 | 0.090 |
Why?
| Cell Transformation, Neoplastic | 1 | 2013 | 184 | 0.090 |
Why?
| Thalidomide | 1 | 2014 | 377 | 0.090 |
Why?
| Follow-Up Studies | 3 | 2024 | 2279 | 0.090 |
Why?
| Flow Cytometry | 2 | 2012 | 478 | 0.090 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2023 | 263 | 0.090 |
Why?
| Leukemia, Promyelocytic, Acute | 1 | 2010 | 12 | 0.090 |
Why?
| Luciferases | 1 | 2010 | 48 | 0.080 |
Why?
| Response Elements | 1 | 2010 | 29 | 0.080 |
Why?
| Gene Silencing | 1 | 2010 | 118 | 0.080 |
Why?
| Alleles | 2 | 2021 | 276 | 0.080 |
Why?
| Tumor Burden | 2 | 2020 | 136 | 0.080 |
Why?
| Transfection | 1 | 2010 | 357 | 0.080 |
Why?
| Recombinant Fusion Proteins | 1 | 2010 | 177 | 0.080 |
Why?
| Molecular Structure | 1 | 2010 | 314 | 0.080 |
Why?
| Histones | 2 | 2021 | 314 | 0.080 |
Why?
| Apoptosis | 2 | 2014 | 1119 | 0.080 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 117 | 0.070 |
Why?
| Syndecan-1 | 2 | 2021 | 74 | 0.070 |
Why?
| Case-Control Studies | 2 | 2024 | 1201 | 0.060 |
Why?
| Tumor Cells, Cultured | 2 | 2020 | 460 | 0.060 |
Why?
| Imaging, Three-Dimensional | 2 | 2017 | 154 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2010 | 990 | 0.060 |
Why?
| Transmembrane Activator and CAML Interactor Protein | 1 | 2024 | 6 | 0.060 |
Why?
| Mendelian Randomization Analysis | 1 | 2024 | 7 | 0.060 |
Why?
| ROC Curve | 1 | 2025 | 253 | 0.060 |
Why?
| Telomere | 1 | 2024 | 38 | 0.060 |
Why?
| Arkansas | 2 | 2021 | 2028 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2024 | 34 | 0.060 |
Why?
| Ferritins | 1 | 2024 | 36 | 0.050 |
Why?
| Killer Cells, Natural | 1 | 2024 | 116 | 0.050 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.050 |
Why?
| X-Ray Microtomography | 1 | 2024 | 79 | 0.050 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2024 | 132 | 0.050 |
Why?
| Antibodies | 1 | 2024 | 159 | 0.050 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2023 | 54 | 0.050 |
Why?
| Demography | 1 | 2023 | 90 | 0.050 |
Why?
| B-Lymphocytes | 1 | 2024 | 184 | 0.050 |
Why?
| Cell Communication | 1 | 2023 | 71 | 0.050 |
Why?
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| Neoplasms | 1 | 2013 | 1325 | 0.050 |
Why?
| Patients | 1 | 2022 | 51 | 0.050 |
Why?
| Geography | 1 | 2022 | 65 | 0.050 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2022 | 34 | 0.050 |
Why?
| Patient Selection | 1 | 2023 | 259 | 0.050 |
Why?
| United States Food and Drug Administration | 1 | 2022 | 98 | 0.050 |
Why?
| Oncogenes | 1 | 2021 | 60 | 0.050 |
Why?
| Infant | 1 | 2010 | 3733 | 0.050 |
Why?
| Phylogeny | 1 | 2022 | 231 | 0.050 |
Why?
| Tomography, X-Ray Computed | 2 | 2017 | 1165 | 0.050 |
Why?
| SOXC Transcription Factors | 1 | 2021 | 13 | 0.040 |
Why?
| Transcriptional Activation | 1 | 2021 | 122 | 0.040 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 106 | 0.040 |
Why?
| Pyrimidines | 1 | 2022 | 199 | 0.040 |
Why?
| Cyclin D2 | 1 | 2020 | 21 | 0.040 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 69 | 0.040 |
Why?
| Aneuploidy | 1 | 2020 | 18 | 0.040 |
Why?
| Proto-Oncogene Proteins c-maf | 1 | 2020 | 19 | 0.040 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.040 |
Why?
| ras Proteins | 1 | 2020 | 64 | 0.040 |
Why?
| Histone Code | 1 | 2020 | 32 | 0.040 |
Why?
| Cyclin D1 | 1 | 2020 | 57 | 0.040 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2020 | 55 | 0.040 |
Why?
| Genome, Human | 1 | 2021 | 121 | 0.040 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2020 | 75 | 0.040 |
Why?
| Protein Kinase Inhibitors | 1 | 2022 | 227 | 0.040 |
Why?
| DNA, Neoplasm | 1 | 2020 | 146 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2020 | 180 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 230 | 0.040 |
Why?
| Osteoclasts | 1 | 2022 | 428 | 0.040 |
Why?
| Health Status Disparities | 1 | 2022 | 215 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2021 | 591 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 182 | 0.040 |
Why?
| Computational Biology | 1 | 2020 | 212 | 0.040 |
Why?
| Gram-Positive Bacterial Infections | 1 | 2019 | 30 | 0.040 |
Why?
| Pseudomonas Infections | 1 | 2019 | 54 | 0.040 |
Why?
| Syndrome | 1 | 2019 | 247 | 0.040 |
Why?
| Fractures, Compression | 1 | 2018 | 17 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2021 | 595 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2020 | 467 | 0.040 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 52 | 0.040 |
Why?
| Protein-Tyrosine Kinases | 1 | 2018 | 87 | 0.040 |
Why?
| False Positive Reactions | 1 | 2017 | 63 | 0.030 |
Why?
| Bone and Bones | 1 | 2021 | 494 | 0.030 |
Why?
| Amino Acid Sequence | 1 | 2018 | 578 | 0.030 |
Why?
| Itraconazole | 1 | 2016 | 38 | 0.030 |
Why?
| beta-Glucans | 1 | 2016 | 23 | 0.030 |
Why?
| Alkaline Phosphatase | 1 | 2017 | 94 | 0.030 |
Why?
| Databases, Factual | 1 | 2020 | 706 | 0.030 |
Why?
| Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| Angiopoietin-1 | 1 | 2016 | 16 | 0.030 |
Why?
| Amphotericin B | 1 | 2016 | 103 | 0.030 |
Why?
| Genes, p53 | 1 | 2016 | 52 | 0.030 |
Why?
| Ileum | 1 | 2016 | 88 | 0.030 |
Why?
| NF-kappa B | 1 | 2018 | 322 | 0.030 |
Why?
| Intestinal Obstruction | 1 | 2016 | 38 | 0.030 |
Why?
| Glycolysis | 1 | 2016 | 73 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2016 | 108 | 0.030 |
Why?
| Colonoscopy | 1 | 2016 | 108 | 0.030 |
Why?
| Models, Genetic | 1 | 2016 | 169 | 0.030 |
Why?
| Genomic Instability | 1 | 2016 | 89 | 0.030 |
Why?
| Fever | 1 | 2016 | 112 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2016 | 136 | 0.030 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2016 | 107 | 0.030 |
Why?
| Staphylococcal Infections | 1 | 2019 | 285 | 0.030 |
Why?
| Logistic Models | 1 | 2018 | 925 | 0.030 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 151 | 0.030 |
Why?
| Heart | 1 | 2017 | 345 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2016 | 443 | 0.030 |
Why?
| Algorithms | 1 | 2018 | 672 | 0.030 |
Why?
| Echocardiography | 1 | 2017 | 415 | 0.030 |
Why?
| Weight Loss | 1 | 2016 | 248 | 0.030 |
Why?
| Megakaryocyte Progenitor Cells | 1 | 2014 | 1 | 0.030 |
Why?
| Young Adult | 1 | 2024 | 4329 | 0.030 |
Why?
| Antifungal Agents | 1 | 2016 | 347 | 0.030 |
Why?
| Longitudinal Studies | 1 | 2016 | 747 | 0.030 |
Why?
| Models, Immunological | 1 | 2013 | 8 | 0.030 |
Why?
| Chemistry, Pharmaceutical | 1 | 2013 | 35 | 0.030 |
Why?
| Early Diagnosis | 1 | 2013 | 95 | 0.020 |
Why?
| Karyotyping | 1 | 2012 | 78 | 0.020 |
Why?
| Azacitidine | 1 | 2012 | 39 | 0.020 |
Why?
| Primary Cell Culture | 1 | 2012 | 62 | 0.020 |
Why?
| Cell Lineage | 1 | 2012 | 85 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2013 | 461 | 0.020 |
Why?
| Child | 1 | 2024 | 7248 | 0.020 |
Why?
| Antigens, CD | 1 | 2012 | 218 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2013 | 372 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2017 | 1546 | 0.020 |
Why?
| Cytokines | 1 | 2013 | 623 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2013 | 1229 | 0.020 |
Why?
| Cohort Studies | 1 | 2013 | 1542 | 0.020 |
Why?
|
|
Schinke's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|